| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01760109 | Respiratory Tract Infections|Urinary Tract Infections | Drug: Piperacillin Sodium and Sulbactam Sodium | Xiangbei Welman Pharmaceutical Co., Ltd | Phase 4 | 2011-07-01 | 2012-12-30 |
| NCT02466438 | Infection | Drug: Piperacillin-tazobactam | St. Justine's Hospital | Phase 1 | 2016-01-01 | 2016-04-18 |
| NCT02730624 | Early Phase of Severe Sepsis and Septic Shock | Drug: Piperacillin-tazobactam | Sutep Jaruratanasirikul|Prince of Songkla University | Phase 4 | 2014-03-01 | 2016-03-31 |
| NCT00703144 | Diffusive and Convective Clearance|Body Clearance|Piperacillin Tazocilline Concentrations (Cmin) | Drug: piperacillin/tazobactam|Procedure: Pharmacokinetic | University Hospital, Toulouse | Phase 4 | 2008-06-01 | 2013-01-23 |
| NCT01897831 | Respiratory Tract Infections|Urinary Tract Infections | Drug: xin te mie | Xiangbei Welman Pharmaceutical Co., Ltd | Phase 4 | 2011-08-01 | 2013-07-09 |
| NCT02753946 | Urinary Tract Infection Symptomatic|Acute Pyelonephritis|Urinary Tract Infection Complicated | Drug: ZTI-01|Drug: Piperacillin-tazobactam | Zavante Therapeutics|Medpace, Inc. | Phase 2|Phase 3 | 2016-04-01 | 2017-01-12 |
| NCT01198925 | Infectious Disease | Drug: piperacillin continuous infusion|Drug: piperacillin extended infusion | University Hospital, Ghent | Phase 4 | 2010-09-01 | 2014-12-04 |
| NCT01923363 | Obesity | Drug: Piperacillin/Tazobactam Standard Dose|Drug: Piperacillin/Tazobactam High Dose | Loma Linda University | | 2014-01-01 | 2016-09-13 |
| NCT02437045 | Bloodstream Infections | Drug: Meropenem|Drug: Piperacillin-tazobactam combination product | The University of Queensland | Phase 4 | 2015-04-01 | 2016-11-13 |
| NCT01694069 | Cystic Fibrosis | Drug: Piperacillin-tazobactam combination product | West Virginia University | Phase 4 | 2012-09-01 | 2014-03-14 |
| NCT02306928 | Septic Shock | Other: Blood draw | University of Aarhus | | 2014-09-01 | 2016-02-09 |
| NCT01796717 | Nosocomial Pneumonia | Drug: C Group|Drug: E Group | Tianjin Medical University Cancer Institute and Hospital|Pfizer | Phase 2|Phase 3 | 2012-03-01 | 2016-02-14 |
| NCT00389987 | Complicated Intra-Abdominal Infections | Drug: MK0826, /Duration of Treatment : 8 Weeks|Drug: Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks | Merck Sharp & Dohme Corp. | Phase 3 | 2001-09-01 | 2017-02-16 |
| NCT01983787 | Cystic Fibrosis | | University of Aarhus | Phase 4 | 2013-07-01 | 2015-11-06 |
| NCT00873327 | Sepsis | Drug: piperacillin-tazobactam | Phillip Brian Smith|Duke University | Phase 1 | 2009-10-01 | 2013-05-29 |
| NCT02176122 | Bloodstream Infections | Drug: Meropenem|Drug: Piperacillin-tazobactam combination product | The University of Queensland|International Society of Chemotherapy|Australian Society for Antimicrobials|Queensland Clinical Trials & Biostatistics Centre|Australasian Society for Infectious Diseases | Phase 4 | 2014-02-01 | 2016-11-15 |
| NCT01714557 | Neutropenia|Hematopoietic Stem Cell Transplantation | Drug: Piperacillin|Drug: Piperacillin-tazobactam combination product | Chinese PLA General Hospital | | 2012-09-01 | 2012-10-25 |
| NCT01370616 | Infection; Diabetic Foot | Drug: Ertapenem sodium|Drug: Piperacillin/tazobactam sodium|Drug: Piperacillin/tazobactam-matching placebo|Drug: Amoxicillin/clavulunate potassium | Merck Sharp & Dohme Corp. | Phase 3 | 2011-09-01 | 2017-02-17 |
| NCT00629135 | Abscess, Intra-Abdominal | Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam | Hannover Medical School|Bayer | Phase 3 | 2005-11-01 | 2011-06-21 |
| NCT01517815 | Septic Shock | Drug: Doripenem or Piperacillin/Tazobactam|Drug: Doripenem or Piperacillin/Tazobactam | University Hospital, Montpellier | | 2012-02-01 | 2016-11-28 |
| NCT00816790 | Septic Shock|Acute Renal Failure | Drug: Piperacillin/Tazobactam|Drug: Piperacillin/Tazobactam | Fraser Health | Phase 4 | 2009-01-01 | 2015-09-10 |
